# arcoris bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arcoris-bio

- Industry: Biotechnology
- Headquarters: Schlieren, Switzerland
- Website: www.arcorisbio.com
- Total disclosed funding: $7.9M
- Latest round: Seed (Oct 7, 2025)
- Investors on record: 5

## About

Based in Switzerland, arcoris bio AG specializes in advanced biomarker detection using innovative technologies for multiplex imaging of nucleic acids and proteins, serving research and clinical laboratories globally. Founded in 2022 in Schlieren, Switzerland, arcoris bio AG focuses on biomarker detection technology. In October 2025, arcoris bio AG raised CHF 6.3 million in seed funding co-led by ZEISS Ventures, Vi Partners and Ventura BioMed Investors, with participation from Redalpine and Zürcher Kantonalbank. Arcoris Bio specializes in advanced biomarker detection through its proprietary MUSE® technology, which employs self-assembling, enzyme-free DNA nanotechnology for multiplex imaging of nucleic acids and proteins. The platform enables simultaneous detection of proteins, DNA, and RNA, facilitating applications such as immunofluorescence and in situ hybridization. Key users include researchers and laboratories in molecular biology and histology, benefiting from the technology’s capacity to handle multiple labels. Arcoris Bio primarily targets markets in Europe, North America, and Asia, providing solutions to academic institutions, clinical laboratories, and biotechnology companies. Arcoris Bio generates revenue through the sale of its MUSE® kits and custom solutions to B2B clients, including research institutions and laboratories. Their flagship products, such as the immunoMUSE and rnaMUSE kits, cater to clients involved in biomarker analysis, with pricing structured for bulk purchases. Partnerships for white-label solutions further enhance revenue potential, allowing tailored applications of MUSE® technology. In October 2025, arcoris bio AG raised CHF 6.3 million in seed funding co-led by ZEISS Ventures, Vi Partners and Ventura BioMed Investors, with participation from Redalpine and Zürcher Kantonalbank. The company will use the funding to industrialize its MUSE biomarker detection platform, expand its business and develop new products.

## Funding rounds

- Seed, Oct 7, 2025, $7.9M — Zürcher Kantonalbank, Vi Partners, Redalpine, Ventura BioMed Investors, ZEISS Ventures

## Investors

- Zürcher Kantonalbank — Seed
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Seed
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Seed
- Ventura BioMed Investors (https://capitalatlas.ai/funds/ventura-biomed-investors) — Seed
- ZEISS Ventures (https://capitalatlas.ai/funds/zeiss-ventures) — Seed